Shisi Pharmaceutical Group (02005) bid for a total of 13 varieties and 16 product specifications, all to be selected for centralized drug procurement nationwide

According to the Zhitong Finance App, Shisi Pharmaceutical Group (02005) issued an announcement. In the recent 12th batch of centralized national drug procurement tenders, the Group proposed a total of 13 varieties of products with 16 product specifications to be selected. Includes: Bunanserin tablets (4mg), betahistine mesylate tablets (6mg), vitamin B6 injection (1ml: 0.1g), aximos capsules (0.25g), doxazosin mesylate sustained-release tablets (4mg), bisoprolol amlodipine tablets (bisoprolol fumarate 5mg and amlodipine benzenesulfonate 5mg), perindopril amlodipine tablets (III) (perindopril 10mg, benzenesulfonate 5mg), nicardipine hydrochloride injection (10ml: 10mg), and nicardipine hydrochloride injection (200ml) : Nicardipine hydrochloride 20mg with sodium chloride 1.72g), bumetanib injection (2ml: 1mg and 1ml: 0.5mg), pentoxacocaine sustained-release tablets (0.4g), dilarose dispersible tablets (125mg), complex potassium hydrogen phosphate injections (5ml: 1.12g of potassium dihydrogen phosphate and 1.18g and 2ml: potassium dihydrogen phosphate 0.448g and dipotassium hydrogen phosphate 0.472g), and calcium chloride injection (10ml: 1g).

Centralized procurement of pharmaceuticals across the country has brought important development opportunities to the Group. The Group actively complies with collection policy guidelines, focuses on increasing product market share, leveraging the advantages of integrated raw materials and large-scale production, effectively controlling production costs, continuously supplying high-quality products, and continuously consolidating market competitiveness.